These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2223395)

  • 21. Cellular immunotherapy of cancer.
    Topalian SL; Rosenberg SA
    Crit Care Med; 1990 Feb; 18(2 Suppl):S144. PubMed ID: 2298029
    [No Abstract]   [Full Text] [Related]  

  • 22. [Adoptive immunotherapy with interleukin-2 and with interleukin-2 activated lymphocytes].
    Eggermont AM; Stoter G; Jansen RL; Bolhuis RL
    Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1387-92. PubMed ID: 2677757
    [No Abstract]   [Full Text] [Related]  

  • 23. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
    Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
    Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Adoptive immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes].
    van de Loosdrecht AA; Ossenkoppele GJ; Beelen RH
    Ned Tijdschr Geneeskd; 1989 Oct; 133(40):1994-5. PubMed ID: 2812087
    [No Abstract]   [Full Text] [Related]  

  • 25. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
    Blacklock JB; Grimm EA
    Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of combined adoptive immunotherapy and radiotherapy on tumor growth.
    Sumareva R; Ukrainsky G; Kiremidjian-Schumacher L; Roy M; Wishe HI; Steinfeld AD; Cooper JS
    Radiat Oncol Investig; 1999; 7(1):22-9. PubMed ID: 10030620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
    Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Locoregional adoptive immunotherapy using LAK cells and IL-2 against liver metastases from digestive tract cancer].
    Ueda Y; Sonoyama T; Itoi H; Fujiwara H; Fuji N; Itoh T; Fujiki H; Yamashita T; Yoshimura T; Harada S; Okugawa K; Yamagishi H
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1962-5. PubMed ID: 11086454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-2: basic biology and therapeutic use.
    Williams TM; Fox KR; Kant JA
    Hematol Pathol; 1991; 5(2):45-55. PubMed ID: 1894582
    [No Abstract]   [Full Text] [Related]  

  • 31. [Tumor metastasis].
    Sekiguchi M
    Nihon Seikeigeka Gakkai Zasshi; 1993 May; 67(5):511-28. PubMed ID: 8336071
    [No Abstract]   [Full Text] [Related]  

  • 32. [The future application of adoptive immunotherapy in treatment of lung cancer].
    Li PS
    Zhonghua Nei Ke Za Zhi; 1993 Sep; 32(9):579-80. PubMed ID: 8112136
    [No Abstract]   [Full Text] [Related]  

  • 33. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokines in anticancer therapy.
    Khan IU; Shear NH
    Clin Dermatol; 1991; 9(4):523-33. PubMed ID: 1726586
    [No Abstract]   [Full Text] [Related]  

  • 35. Tumor infiltrating lymphocytes.
    Davidson AT
    J Natl Med Assoc; 1990 Sep; 82(9):612-3, 616. PubMed ID: 2213908
    [No Abstract]   [Full Text] [Related]  

  • 36. Easing the side effects of IL-2-LAK cell therapy.
    Oncology (Williston Park); 1988 May; 2(5):61, 64. PubMed ID: 3275159
    [No Abstract]   [Full Text] [Related]  

  • 37. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
    Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Rosenberg SA
    Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
    [No Abstract]   [Full Text] [Related]  

  • 39. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.
    Lillehei KO; Johnson SD; McCleary EL; Mitchell DH; Schiltz PM; Kruse CA
    Online J Curr Clin Trials; 1993 Dec; Doc No 111():[806 words; 5 paragraphs]. PubMed ID: 8305997
    [No Abstract]   [Full Text] [Related]  

  • 40. [The observation on treatment effects of local adoptive immunotherapy in 33 cases with head and neck cancer].
    Han D; Zhu X; Huang Z
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):454-6. PubMed ID: 10920882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.